Latest news with #ShivaniAggarwal
Yahoo
10 hours ago
- Health
- Yahoo
Landmark Science announces research to be presented at ISPE 2025
At this year's conference, Landmark Science spotlights real-world evidence's power to drive GLP-1 and Wegovy insights in Medicare and shape regulatory decision-making. LOS ANGELES, Aug. 19, 2025 /PRNewswire/ -- Landmark Science today announced its presence at International Society for Pharmacoepidemiology (ISPE) 2025 annual conference, in collaboration with Innovaccer, set to take place August 22–26 in Washington D.C. Landmark Science's real-world data is featured across five pieces of research to be presented at the conference. The research provides a timely look into patient populations initiating GLP-1 receptor agonists (RAs), offering new insights into the characteristics of Medicare patients initiating these therapies. They also offer a special focus on Medicaid patients initiating Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction — an area of growing importance as GLP-1 RAs expand beyond diabetes management. "GLP-1s are on the rise in Medicare — from Type 2 diabetes and obesity to cardiovascular risk reduction, kidney disease, obstructive sleep apnea, and noncirrhotic MASH, indications for GLP-1s have expanded fast. But not a lot is known about utilization in a Medicare population. Real-world evidence is essential in understanding prescribing patterns, patient outcomes, and safety profiles, ultimately guiding optimal care strategies and policy decisions for Medicare beneficiaries," said Shivani Aggarwal, CEO. "The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity," said Puneet Budhiraja - Vice President, Analytics at Humbi AI by Innovaccer. "At ISPE, we're excited to share data that helps stakeholders better understand who is initiating these therapies — and who might be left behind." At this year's ISPE, Landmark epidemiologists are also generating novel methodologies that will shape the future of evidence generation used to support regulatory decision-making. "Our research uncovers nuanced trends and synthesizes them into transparent, evidenced based research—to showcase and drive the utility of real-world evidence in regulatory decision-making," said Shivani Aggarwal. Highlights include: Two poster presentations on Medicare beneficiaries initiating GLP-1 RAs and Wegovy. Two poster presentations underscoring RWE's potential for use in regulatory decision-making. A poster presentation introducing a framework operationalizing regulatory guidelines into key steps for submission success. Schedule a meeting with Landmark Science at ISPE 2025, and learn more about our abstracts and events, including workshops and panels. Follow Landmark Science on LinkedIn for more updates from #ISPE2025. Poster Discussions and Presentations Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-032 Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population Focusing specifically on Wegovy, this analysis offers a more granular view into who Wegovy initiators are, how they responded, and what happened after Wegovy became an option for cardiovascular protection. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-033 Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs) Real-world evidence use is growing but still has mixed acceptance. Here we synthesize emerging patterns into actionable insights for success. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-079 Evaluation of Real-World Evidence in Regulatory and HTA Submissions Real-world evidence isn't judged the same everywhere — and the differences matter. We review feedback from regulatory and key HTA bodies to describe the acceptability of RWE in marketing applications. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-080 Framework for Real-World Data Used in Regulatory Submissions Discover our framework, which operationalizes regulatory guidelines about real-world data into key steps for submission readiness. - Tuesday Aug 26, 2025 | Hall D | Poster Session C: 12:00 PM – 1:30 PM- Poster Code: C-124 About Landmark Science, Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE to help patients. Landmark Science's team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, regulators, and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit or contact info@ Media Contact:Landmark Sciencemedia@ (424) 535-3011https:// View original content to download multimedia: SOURCE Landmark Science, Inc
National Post
30-04-2025
- Business
- National Post
Humbi AI by Innovaccer and Landmark Science to Present Real-World Evidence on GLP-1 Use for Cardiometabolic and Cardiovascular Risk Reduction in Medicare Populations at ISPOR 2025
Article content Article content Article content MONTREAL — Innovaccer, the leading healthcare AI company, today announced that its recently acquired actuarial science company – Humbi AI, in collaboration with Landmark Science, Inc., will present a joint research at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 annual conference, scheduled to take place between May 13–16 in Montreal, QC, Canada. Article content The research offers new insights into the characteristics of Medicare patients initiating GLP-1 receptor agonists (RAs) and Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction. Article content The research, leveraging Humbi AI's high-quality real-world Medicare dataset, provides a timely look into patient populations initiating these therapies—an area of growing importance as GLP-1 RAs expand beyond diabetes management. Article content 'The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity,' said Puneet Budhiraja – Vice President, Analytics at Humbi AI by Innovaccer. 'At ISPOR, we're excited to share data that helps stakeholders better understand who is initiating these therapies – and who might be left behind.' Article content 'The importance of real-world evidence in understanding semaglutide's impact on cardiovascular disease among Medicare patients cannot be overstated, particularly given the risk of heart attack and stroke among this older population,' said Shivani Aggarwal – CEO of Landmark Science. Article content The two joint poster presentations by HumbiAI and Landmark Science, Inc. include: Article content Poster #EPH74 (Poster Session 2, 14th May, 4:00PM – 7:00PM): Characteristics of Patients Initiating Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments. View Poster Abstract Article content Humbi AI by Innovaccer is an actuarial intelligence company powered by Medicare, Medicaid, and Commercial datasets enabling providers, payers, and life sciences organizations to manage risk, improve performance, and succeed in value-based care. With deep actuarial expertise, robust benchmarking data, and flexible financial modeling software, Humbi AI provides powerful analytics and consultative services that transform complex challenges into actionable insights. By simplifying risk management and enhancing decision-making, Humbi AI by Innovaccer helps organizations drive better outcomes and sustainable growth. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Article content Article content
